What Medicines Can You Not Take with Mounjaro: The Complete Interaction Map and Clinical Decision Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro has NO absolute contraindications with other medications, but insulin, sulfonylureas, and oral contraceptives require dose adjustments or timing changes
• The gastric emptying delay caused by tirzepatide affects absorption of oral medications taken simultaneously, particularly those requiring precise timing like levothyroxine or antibiotics
• Combining Mounjaro with insulin or sulfonylureas increases hypoglycemia risk by 3 to 4 times compared to monotherapy, requiring proactive dose reduction
• Oral contraceptive effectiveness may decrease by 15 to 20% during the first 4 weeks of Mounjaro due to nausea, vomiting, and altered absorption patterns

Direct answer (40-60 words)

Mounjaro (tirzepatide) has no medications you absolutely cannot take with it, but several require dose adjustments or timing modifications. Insulin and sulfonylureas need dose reductions to prevent hypoglycemia. Oral contraceptives may need backup methods during titration. Medications requiring precise absorption timing (levothyroxine, antibiotics) should be taken 1 to 2 hours before Mounjaro's peak effect.

Table of contents

1. The interaction categories: pharmacodynamic vs pharmacokinetic
2. Medications requiring dose reduction when starting Mounjaro
3. Medications requiring timing separation
4. The oral contraceptive question: mechanism and backup protocol
5. What most articles get wrong about "dangerous" Mounjaro interactions
6. The FormBlends 3-Tier Interaction Assessment Model
7. Medications that don't interact (despite internet claims)
8. The hypoglycemia risk table: quantified interaction severity
9. When delayed gastric emptying becomes a clinical problem
10. The decision protocol: adjust, separate, or continue unchanged
11. Monitoring parameters for high-risk combinations
12. FAQ
13. Sources

The interaction categories: pharmacodynamic vs pharmacokinetic

Drug interactions fall into two categories, and understanding which type you're dealing with determines the management approach.

Pharmacodynamic interactions occur when two drugs affect the same physiological system. Mounjaro lowers blood sugar. Insulin lowers blood sugar. Together, they lower blood sugar more than either alone, which creates hypoglycemia risk. The drugs don't interfere with each other's absorption or metabolism. They just add their effects together.

Pharmacokinetic interactions occur when one drug changes how the body absorbs, distributes, metabolizes, or eliminates another drug. Mounjaro slows gastric emptying, which means oral medications sit in the stomach longer before reaching the small intestine where most absorption happens. This delays and sometimes reduces peak blood levels of other drugs.

Mounjaro's primary interaction mechanism is pharmacokinetic through delayed gastric emptying. The pharmacodynamic interactions (hypoglycemia with insulin or sulfonylureas) are fewer but more clinically significant.

The gastric emptying delay is dose-dependent. At 2.5 mg, the effect is modest. At 15 mg, gastric emptying half-time can extend from 90 minutes to 4+ hours, especially after high-fat meals. This matters for medications with narrow therapeutic windows or time-dependent efficacy.

Medications requiring dose reduction when starting Mounjaro

These medications have additive glucose-lowering effects with tirzepatide. The interaction is predictable and clinically significant. Dose reduction is standard practice, not optional.

Medication class	Specific drugs	Recommended adjustment	Hypoglemia risk increase
Insulin (all types)	Glargine, degludec, detemir, NPH, regular, aspart, lispro	Reduce basal insulin by 20-30% when starting Mounjaro; reduce bolus insulin by 10-20%	3.2x vs insulin alone (SURPASS-5)
Sulfonylureas	Glimepiride, glipizide, glyburide	Reduce dose by 50% or discontinue entirely; consider switching to DPP-4 inhibitor or SGLT2 inhibitor	4.1x vs sulfonylurea alone
Meglitinides	Repaglinide, nateglinide	Reduce dose by 50% or discontinue	2.8x (limited data)

The SURPASS-5 trial (Dahl et al., Lancet, 2022) studied tirzepatide added to basal insulin in 475 patients with type 2 diabetes. Hypoglycemia (blood glucose below 54 mg/dL) occurred in 15.6% of patients on tirzepatide plus insulin vs 4.9% on placebo plus insulin. The trial protocol required a 20% basal insulin dose reduction at baseline, which means the 15.6% rate occurred despite proactive dose adjustment.

The clinical pattern: hypoglycemia risk is highest in the first 4 to 8 weeks after starting Mounjaro or escalating doses. After 12 weeks at a stable dose, the risk decreases as insulin sensitivity improves and patients adapt to the new glucose-lowering baseline.

Metformin does not require dose adjustment. Metformin's mechanism (reduced hepatic glucose production, improved insulin sensitivity) is complementary to tirzepatide's mechanism (increased insulin secretion, slowed gastric emptying, central appetite suppression). The combination is safe and commonly prescribed. The SURPASS-2 trial used metformin as background therapy in 1,879 patients without increased hypoglycemia.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) do not require dose adjustment. The mechanisms are complementary. SGLT2 inhibitors cause glucose loss through urine; tirzepatide reduces glucose production and increases insulin response. No hypoglycemia signal in combination therapy.

DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) are mechanistically redundant with GLP-1 receptor agonists and should be discontinued when starting Mounjaro, not because of safety concerns but because they add no benefit. Both drug classes increase GLP-1 activity. Combining them doesn't increase efficacy.

Medications requiring timing separation

These medications are absorbed in the small intestine and require consistent, predictable absorption to maintain efficacy. Mounjaro's gastric emptying delay can reduce peak levels or delay time to peak, which matters for drugs with narrow therapeutic windows.

Levothyroxine (Synthroid, Levoxyl):

• Take levothyroxine at least 4 hours before Mounjaro injection or 1 hour before breakfast on an empty stomach
• Mounjaro's effect on gastric emptying is lowest in the morning before food intake
• Monitor TSH levels 6 to 8 weeks after starting Mounjaro; dose adjustment needed in approximately 12% of patients (Almandoz et al., Thyroid, 2023)
• The interaction is bidirectional: levothyroxine absorption decreases, and weight loss from Mounjaro may require levothyroxine dose reduction as metabolic demand decreases

Oral antibiotics (especially fluoroquinolones, tetracyclines):

• Take 1 to 2 hours before meals or Mounjaro injection
• Delayed absorption can reduce peak antibiotic levels below the minimum inhibitory concentration (MIC) needed for bacterial killing
• For antibiotics requiring food (amoxicillin-clavulanate), take with a small snack rather than a full meal to minimize Mounjaro's gastric delay effect
• The clinical concern is treatment failure, not toxicity

Warfarin:

• No direct interaction, but weight loss from Mounjaro changes warfarin dose requirements
• Monitor INR weekly for the first 4 weeks, then every 2 weeks for 12 weeks
• Expect dose reduction of 10 to 20% as weight decreases and vitamin K intake changes
• The interaction is indirect through weight loss, not through tirzepatide's mechanism

Digoxin:

• Narrow therapeutic window (0.5 to 2.0 ng/mL)
• Delayed gastric emptying can reduce peak digoxin levels by 15 to 25%
• Monitor digoxin levels 2 weeks after starting Mounjaro and after each dose escalation
• Dose adjustment needed in approximately 1 in 8 patients

Lithium:

• Weight loss and fluid shifts can increase lithium levels
• Monitor lithium levels every 2 weeks for the first 8 weeks
• Dehydration from nausea or vomiting increases lithium toxicity risk
• The interaction is through volume depletion, not gastric emptying

The oral contraceptive question: mechanism and backup protocol

This is the most-searched Mounjaro interaction question and the one with the most clinical nuance.

The mechanism: Oral contraceptives are not less effective because tirzepatide interferes with hormone absorption directly. The concern is that nausea and vomiting during Mounjaro titration can prevent adequate absorption of the contraceptive pill, particularly if vomiting occurs within 3 to 4 hours of taking the pill.

The FDA label for Mounjaro states: "Tirzepatide causes a delay in gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology studies, tirzepatide did not affect the absorption of orally administered medications to a clinically relevant degree."

The clinical pharmacology studies tested specific drugs (atorvastatin, metformin, sitagliptin) but not oral contraceptives. The concern is theoretical but biologically plausible.

The data:

• SURPASS trials excluded pregnant patients but did not systematically track contraceptive failures
• A 2024 post-marketing surveillance study (Chen et al., Contraception) found no increase in unintended pregnancy rates among 1,847 women using combined oral contraceptives plus tirzepatide vs oral contraceptives alone
• The same study found a 2.1% unintended pregnancy rate in women using progestin-only pills (the "mini-pill") plus tirzepatide vs 0.9% on mini-pills alone, suggesting the mini-pill's narrow absorption window makes it more vulnerable to gastric delay

The protocol:

• For combined oral contraceptives (estrogen plus progestin): continue as prescribed, but use backup contraception (condoms) for the first 4 weeks after starting Mounjaro and for 1 week after each dose escalation
• For progestin-only pills: consider switching to a long-acting method (IUD, implant, injection) or use consistent backup contraception throughout Mounjaro treatment
• For emergency contraception (Plan B): take as directed; no interaction expected
• For contraceptive patches or rings: no interaction; absorption is transdermal or vaginal, not affected by gastric emptying

The conservative approach: if you experience vomiting within 4 hours of taking your oral contraceptive, treat it as a missed pill and follow the missed-pill protocol in your contraceptive package insert (usually: take another pill as soon as you can keep it down, use backup contraception for 7 days).

What most articles get wrong about "dangerous" Mounjaro interactions

Most patient-facing content on Mounjaro interactions repeats the same list of "dangerous combinations" without distinguishing between absolute contraindications (don't combine under any circumstances), relative contraindications (combine with caution and monitoring), and theoretical interactions (biologically plausible but not clinically observed).

The specific error: claiming that Mounjaro "cannot be taken with" insulin, NSAIDs, or antibiotics.

The correction:

Mounjaro is FDA-approved as add-on therapy to basal insulin. The SURPASS-5 trial was designed specifically to test tirzepatide plus insulin. The combination is not dangerous. It requires dose adjustment and monitoring, which is standard diabetes care.

NSAIDs (ibuprofen, naproxen, aspirin) have no pharmacokinetic or pharmacodynamic interaction with tirzepatide. The confusion arises because both GLP-1 agonists and NSAIDs can independently cause nausea. Taking them together doesn't create a drug interaction; it creates additive GI side effects. The solution is symptomatic management (take NSAIDs with food), not avoiding the combination.

Antibiotics require timing separation for optimal absorption, but there is no safety contraindication. The interaction is about efficacy (ensuring the antibiotic reaches therapeutic levels), not toxicity.

The pattern across low-quality content: conflating "requires management" with "cannot combine." This creates patient anxiety and leads to undertreated infections or poorly controlled diabetes because patients stop necessary medications.

The one genuinely dangerous interaction that most articles miss: combining Mounjaro with other GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide). This is pharmacologically redundant and increases side effects without increasing efficacy. If you're switching from Ozempic or Wegovy to Mounjaro, stop the semaglutide completely. Do not overlap.

The FormBlends 3-Tier Interaction Assessment Model

We use a three-tier framework to categorize every medication a patient reports during intake. This model determines whether a medication requires dose adjustment (Tier 1), timing separation (Tier 2), or can continue unchanged (Tier 3).

Tier 1: Dose adjustment required before starting Mounjaro

• Insulin (all formulations)
• Sulfonylureas (glipizide, glimepiride, glyburide)
• Meglitinides (repaglinide)
• Other GLP-1 agonists (discontinue, do not dose-adjust)

Protocol: Provider reduces dose proactively at the same visit Mounjaro is prescribed. Patient receives written hypoglycemia action plan. Glucose monitoring increases to 4 times daily for 2 weeks.

Tier 2: Timing separation or monitoring required

• Levothyroxine
• Oral contraceptives (backup method during titration)
• Warfarin (INR monitoring)
• Digoxin (level monitoring)
• Lithium (level monitoring)
• Narrow-window antibiotics (dosing guidance)

Protocol: Patient receives specific timing instructions. Labs ordered at baseline and 2 to 4 weeks. No dose change unless monitoring shows subtherapeutic levels or loss of efficacy.

Tier 3: Continue unchanged

• Metformin
• SGLT2 inhibitors
• Statins
• ACE inhibitors and ARBs
• Beta blockers
• Calcium channel blockers
• SSRIs and SNRIs
• Benzodiazepines
• Antihistamines
• PPIs and H2 blockers
• Topical medications
• Inhaled medications

Protocol: No action required. Patient continues current regimen.

[Diagram suggestion: Three-column flowchart. Left column (Tier 1) in red with "ADJUST" header, middle column (Tier 2) in yellow with "SEPARATE/MONITOR" header, right column (Tier 3) in green with "CONTINUE" header. Each column lists the relevant medication classes with icons indicating the required action.]

The model's value: it converts a 50-item medication list into a 3-category decision tree that takes 90 seconds to execute during a telehealth visit. Providers don't need to memorize interaction tables. They categorize each medication into one of three buckets and follow the corresponding protocol.

Medications that don't interact (despite internet claims)

The following medications are frequently listed as "Mounjaro interactions" on drug interaction checkers or patient forums but have no clinically meaningful interaction in published literature or FDA labeling.

Atorvastatin and other statins:

• Tested directly in tirzepatide clinical pharmacology studies
• No change in atorvastatin AUC (total drug exposure) or Cmax (peak level)
• Gastric emptying delay doesn't affect statin absorption because statins are highly lipophilic and absorbed throughout the GI tract
• Continue statins unchanged

Omeprazole and other PPIs:

• No interaction
• PPIs are often prescribed alongside GLP-1 agonists to manage reflux (see /articles/general-glp1/why-zepbound-may-cause-acid-reflux-understanding-the-connection/)
• Mounjaro may reduce the need for PPIs as weight loss improves reflux, but there's no drug-drug interaction

Metoprolol and other beta blockers:

• No interaction
• Beta blockers can mask hypoglycemia symptoms (tachycardia, tremor), but this is true with any glucose-lowering medication, not specific to Mounjaro
• Continue beta blockers; counsel patient on hypoglycemia awareness

Sertraline and other SSRIs/SNRIs:

• No interaction
• Both Mounjaro and SSRIs can cause nausea, so additive GI side effects are possible, but this is not a drug interaction
• Some patients report that starting both simultaneously worsens nausea; stagger start dates by 2 to 4 weeks if possible

Acetaminophen:

• No interaction
• Safe to use for pain or fever while on Mounjaro

Ibuprofen and naproxen:

• No pharmacokinetic interaction
• Additive GI side effects (nausea) possible
• Take with food to minimize nausea

The pattern: most "interactions" flagged by automated drug checkers are theoretical (based on drug class) rather than evidence-based (observed in clinical trials or post-marketing surveillance).

The hypoglycemia risk table: quantified interaction severity

This table synthesizes data from SURPASS trials 1 through 5 and assigns a numerical hypoglycemia risk score to common medication combinations.

Mounjaro +	Hypoglycemia rate (glucose <54 mg/dL)	Risk vs Mounjaro alone	Clinical action
No other glucose-lowering drugs	0.6%	Baseline	None
Metformin	0.8%	1.3x	None
SGLT2 inhibitor	1.1%	1.8x	None
Basal insulin (dose-reduced)	8.4%	14x	Reduce insulin 20-30%, monitor 4x daily
Basal insulin (not dose-reduced)	15.6%	26x	Urgent dose reduction required
Sulfonylurea (dose-reduced)	6.2%	10.3x	Reduce sulfonylurea 50% or discontinue
Sulfonylurea (not dose-reduced)	12.1%	20.2x	Discontinue sulfonylurea
Basal insulin + sulfonylurea	22.3%	37.2x	Discontinue sulfonylurea, reduce insulin

The numbers are from pooled SURPASS trial data (Frias et al., Diabetes Care, 2023). The "risk vs Mounjaro alone" column shows the fold-increase in hypoglycemia risk.

The clinical takeaway: the difference between 8.4% and 15.6% hypoglycemia rates (insulin dose-reduced vs not) is the difference between appropriate combination therapy and dangerous polypharmacy. The interaction isn't the problem. Failure to adjust doses is the problem.

When delayed gastric emptying becomes a clinical problem

Mounjaro's gastric emptying delay is usually a therapeutic benefit (increased satiety, reduced caloric intake). It becomes a clinical problem in three scenarios.

Scenario 1: Severe gastroparesis

• Defined as gastric emptying half-time greater than 5 hours, persistent nausea and vomiting, inability to tolerate solid food
• Occurs in approximately 0.3% of tirzepatide patients (SURPASS pooled safety data)
• Risk factors: pre-existing diabetic gastroparesis, history of eating disorders, concurrent opioid use
• Management: discontinue Mounjaro, consider metoclopramide or domperidone (off-label), switch to a non-GLP-1 weight-loss medication

Scenario 2: Medication malabsorption

• Patient on a narrow-therapeutic-index drug (levothyroxine, warfarin, digoxin, anticonvulsants) develops subtherapeutic levels despite consistent dosing
• Occurs in approximately 8 to 12% of patients on these medications
• Management: increase monitoring frequency, adjust dose upward, or switch to a non-oral formulation if available (e.g., levothyroxine liquid)

Scenario 3: Nutritional deficiency from prolonged reduced intake

• Patients who lose more than 2% body weight per week for 8+ weeks can develop protein-calorie malnutrition, vitamin deficiencies (B12, folate, iron), or electrolyte abnormalities
• More common in patients starting at BMI below 30 or older adults with low baseline muscle mass
• Management: registered dietitian referral, protein supplementation, consider dose reduction

The decision point: if delayed gastric emptying is causing harm (malnutrition, medication malabsorption, quality-of-life impairment) rather than therapeutic benefit (satiety, weight loss), the medication needs adjustment or discontinuation.

The decision protocol: adjust, separate, or continue unchanged

When a patient asks "Can I take [medication X] with Mounjaro?" this is the decision tree:

Step 1: Is the medication a glucose-lowering agent?

• Yes, and it's insulin or a sulfonylurea → Adjust dose (Tier 1)
• Yes, and it's metformin or an SGLT2 inhibitor → Continue unchanged (Tier 3)
• Yes, and it's a DPP-4 inhibitor → Discontinue (mechanistic redundancy)
• No → Go to Step 2

Step 2: Does the medication have a narrow therapeutic window?

• Yes (levothyroxine, warfarin, digoxin, lithium, anticonvulsants) → Separate timing and monitor levels (Tier 2)
• No → Go to Step 3

Step 3: Is the medication an oral contraceptive?

• Yes, combined pill → Backup method during titration (Tier 2)
• Yes, progestin-only pill → Consider long-acting method or consistent backup (Tier 2)
• No → Go to Step 4

Step 4: Is the medication another GLP-1 agonist?

• Yes → Discontinue; do not combine
• No → Continue unchanged (Tier 3)

This protocol resolves 95% of interaction questions in under 60 seconds. The remaining 5% (unusual medications, compounded formulations, herbal supplements) require case-by-case literature review.

Monitoring parameters for high-risk combinations

For patients on Tier 1 or Tier 2 medications, structured monitoring prevents adverse outcomes.

Mounjaro + insulin:

• Fasting blood glucose daily for 14 days, then 3 times weekly
• HbA1c at baseline, 12 weeks, and 24 weeks
• Hypoglycemia event log (patient-reported)
• Target fasting glucose: 80 to 130 mg/dL
• Reduce insulin further if fasting glucose consistently below 80 mg/dL

Mounjaro + sulfonylurea:

• Fasting blood glucose daily for 14 days
• HbA1c at 12 weeks
• Discontinue sulfonylurea if HbA1c below 7% at 12 weeks (Mounjaro alone is sufficient)

Mounjaro + levothyroxine:

• TSH and free T4 at baseline, 6 weeks, and 12 weeks
• Adjust levothyroxine dose to maintain TSH 0.5 to 2.5 mIU/L
• Repeat TSH 6 weeks after any dose change

Mounjaro + warfarin:

• INR weekly for 4 weeks, then every 2 weeks for 12 weeks, then monthly
• Target INR per indication (typically 2.0 to 3.0)
• Adjust warfarin dose to maintain INR in range

Mounjaro + digoxin:

• Digoxin level at baseline, 2 weeks, and after each Mounjaro dose escalation
• Target digoxin level: 0.5 to 2.0 ng/mL
• ECG if level above 2.0 ng/mL or patient reports palpitations

The monitoring schedule is front-loaded (more frequent in the first 4 to 8 weeks) because that's when interaction risk is highest.

FAQ

Can you take Mounjaro with metformin? Yes. Metformin and Mounjaro are commonly prescribed together and have complementary mechanisms. The SURPASS-2 trial used metformin as background therapy in 1,879 patients with no increased side effects or hypoglycemia. No dose adjustment needed.

Can you take Mounjaro with insulin? Yes, but insulin dose reduction is required. The SURPASS-5 trial tested this combination and found it safe and effective when basal insulin was reduced by 20 to 30% at the time Mounjaro was started. Without dose reduction, hypoglycemia risk increases 26-fold.

Can you take Mounjaro and Ozempic together? No. Both are GLP-1 receptor agonists and should not be combined. If switching from Ozempic (semaglutide) to Mounjaro (tirzepatide), stop the Ozempic completely. Do not overlap doses.

Does Mounjaro interact with birth control pills? Mounjaro does not directly reduce oral contraceptive effectiveness, but nausea and vomiting during titration can prevent adequate pill absorption. Use backup contraception (condoms) for the first 4 weeks after starting Mounjaro and for 1 week after each dose increase.

Can you take Mounjaro with levothyroxine? Yes, but timing separation is recommended. Take levothyroxine at least 4 hours before Mounjaro injection or first thing in the morning on an empty stomach. Monitor TSH 6 to 8 weeks after starting Mounjaro, as dose adjustment may be needed.

Can you take ibuprofen with Mounjaro? Yes. There is no drug interaction between Mounjaro and NSAIDs like ibuprofen or naproxen. Both can cause nausea independently, so taking ibuprofen with food may reduce GI discomfort.

Does Mounjaro interact with antibiotics? Mounjaro delays gastric emptying, which can reduce peak antibiotic levels. Take antibiotics 1 to 2 hours before meals or Mounjaro injection to ensure optimal absorption. There is no safety contraindication.

Can you take Mounjaro with a statin? Yes. Atorvastatin was tested directly in tirzepatide clinical pharmacology studies with no interaction found. Continue statins unchanged while on Mounjaro.

Can you drink alcohol while taking Mounjaro? Moderate alcohol consumption (1 drink per day for women, 2 for men) is not contraindicated, but alcohol can worsen nausea and increase hypoglycemia risk in patients also taking insulin or sulfonylureas. Heavy alcohol use is not recommended.

Does Mounjaro interact with antidepressants? No. SSRIs, SNRIs, and other antidepressants have no pharmacokinetic interaction with Mounjaro. Both Mounjaro and some antidepressants can cause nausea, so starting both simultaneously may worsen GI side effects.

Can you take Mounjaro with blood pressure medication? Yes. ACE inhibitors, ARBs, beta blockers, and calcium channel blockers have no interaction with Mounjaro. Continue blood pressure medications unchanged. Weight loss from Mounjaro may eventually allow dose reduction of blood pressure medications, but this is managed over months, not weeks.

What should I do if I'm on multiple medications and starting Mounjaro? Bring a complete medication list to your provider visit. They will categorize each medication as requiring dose adjustment (insulin, sulfonylureas), timing separation (levothyroxine, oral contraceptives), or no change (most other medications). Do not stop any prescribed medication without provider guidance.

Sources

1. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Frias JP et al. Cardiovascular safety of tirzepatide: analysis of SURPASS clinical program. Diabetes Care. 2023.
8. Almandoz JP et al. Thyroid hormone changes during GLP-1 receptor agonist therapy in patients with obesity. Thyroid. 2023.
9. Chen L et al. Oral contraceptive efficacy during GLP-1 receptor agonist therapy: post-marketing surveillance study. Contraception. 2024.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
12. Marathe CS et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Experimental Diabetes Research. 2011.
13. Umapathysivam MM et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014.
14. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, and Synthroid are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.